Tuesday, November 18, 2025 12:01:43 PM
FactaNonVerba 31m on ST-
SAVXL Hi all, last post following a cc with Anavex one hour ago:
- "negative sentiment" in the PR means
"outright rejection to be published in December" - make no mistake on that
- 20 min discussion was mainly on ADL missed endpoint
- new Abclear data etc. was presented briefly
- after the rejection, and what they are currently doing, they will prepare an appeal
- that can take up to 6 months, so patience still needed
- my spoc didn't know the voting process, appears CM is very secretive on all that, which is typically Chris, but not good for the shareholders
- logistics etc. are covered in scenario's with partners, but no partnership deals on the table (not sure they would really tell me)
So the odds same ok on the medium run, but not on the short run. Make no mistake on that.
All the best, I recreated my account to share you that information. I will restep in at crazy low pricing, but not at current levels. Failed Rett (no appeal?) , failed AZ (appeal). No short term meaningfull events IMHO
SAVXL Hi all, last post following a cc with Anavex one hour ago:
- "negative sentiment" in the PR means
"outright rejection to be published in December" - make no mistake on that
- 20 min discussion was mainly on ADL missed endpoint
- new Abclear data etc. was presented briefly
- after the rejection, and what they are currently doing, they will prepare an appeal
- that can take up to 6 months, so patience still needed
- my spoc didn't know the voting process, appears CM is very secretive on all that, which is typically Chris, but not good for the shareholders
- logistics etc. are covered in scenario's with partners, but no partnership deals on the table (not sure they would really tell me)
So the odds same ok on the medium run, but not on the short run. Make no mistake on that.
All the best, I recreated my account to share you that information. I will restep in at crazy low pricing, but not at current levels. Failed Rett (no appeal?) , failed AZ (appeal). No short term meaningfull events IMHO
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
